Home > Riviste > Minerva Surgery > Fascicoli precedenti > Minerva Surgery 2023 October;78(5) > Minerva Surgery 2023 October;78(5):537-44

ULTIMO FASCICOLO
 

JOURNAL TOOLS

Opzioni di pubblicazione
eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

REVIEW   

Minerva Surgery 2023 October;78(5):537-44

DOI: 10.23736/S2724-5691.23.09868-4

Copyright © 2023 EDIZIONI MINERVA MEDICA

lingua: Inglese

Acute graft versus host disease after liver transplantation: where do we stand?

Alessandro IZZO 1, Roberta A. PELLEGRINO 1, Giorgia LOCCI 2, Manuela CESARETTI 1

1 Department of HPB and Liver Transplantation, Brotzu Hospital, Cagliari, Italy; 2 Department of Pathology, Brotzu Hospital, Cagliari, Italy



Graft-versus-host disease (GVHD) is a rare complication after liver transplantation (LT), with an estimated incidence rate of 0.5% to 2% and a mortality rate as high as 75%. The classical target organs of GVHD include the intestines, liver, and skin. The damage of these organs is not easy to detect for the clinician as there is no widely accepted clinical or laboratory diagnostic tests; as a result, diagnosis and initiation of therapy are often delayed. Moreover, without prospective clinical trials to reference, evidence guiding therapy is limited. This review summarized the current knowledge, the potential applications and the clinical relevance of GVHD after LT, highlighting novel approaches in grading and management of GVHD.


KEY WORDS: Liver transplantation; Graft vs. host disease; Chimerism; Transplantation immunology

inizio pagina